Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta, Emily Cheney, Christina Hartl, Constantia Pantelidou, Madisson Oliwa, Jessica A. Castrillon, Jia‐Ren Lin, Katie E. Hurst, Mateus de Oliveira Taveira, Nathan Johnson, William M. Oldham, Marian Kalocsay, Matthew J. Berberich, Sarah A. Boswell, Aditi Kothari, Shawn F. Johnson, Deborah Dillon, Mikel Lipschitz, Scott J. Rodig, Sandro Santagata, Judy E. Garber, Nadine Tung, José Yélamos, Jessica E. Thaxton, Elizabeth A. Mittendorf, Peter K. Sorger, Geoffrey I. Shapiro, Jennifer L. Guerriero
Topics & Concepts
Triple-negative breast cancerCancer researchPARP inhibitorImmune systemReprogrammingImmunotherapyTumor microenvironmentBreast cancerBiologyInnate immune systemImmunologyCancerPoly ADP ribose polymeraseCellBiochemistryGeneticsPolymeraseGenePARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersDNA Repair Mechanisms